The Weekly Roundup: March 10-14

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Biologic-Naïve Patients with Psoriasis Have a Reduced Risk of Psoriatic Arthritis, Based on NPF Target Goals

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

Peter Lio, MD: Minimizing Discomfort in Dermatologic Procedures

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Jeff Stark, MD: Discussing Bimzelx’s Efficacy and Future in Treating Inflammatory Skin Diseases

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

L'Oréal Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns

The recall includes L'Oréal's Effaclar Duo product.

Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

Michael Gold, MD: Insights on Silicone, Energy-Based Devices, and Radiation Therapy

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

How to Avoid Complications With Radiofrequency and Ultrasound-Based Technologies

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Day 4 Recap: AAD 2025

Catch up on coverage from the fourth day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Icotrokinra Demonstrates Promise in Phase 3 ICONIC-LEAD and ICONIC-ADVANCE for Plaque Psoriasis

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Top 5 Articles of the Week: March 2-7

Explore the top headlines of the week including insights on the environmental impact of conferences, new clinical data, and the shift towards more natural-looking results.

Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Lebrikizumab Shows 3-Year Sustained Efficacy in AD

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Michael Gold, MD: Advances in Acne Treatment and Energy-Based Devices

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

Late-Breaking ESK-001 Data from the OLE STRIDE Trial Presented at AAD 2025

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

Dermatology Times' Weekly Crossword: AAD Annual Meeting Insights Edition

Test your knowledge of key words and terms associated with dermatology meeting news from the previous week.

Day 5 Recap: AAD 2025

Catch up on coverage from the final day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Journal Digest: March 12

This review of the latest dermatologic studies includes insights into erectile dysfunction in dermatology and venereology, diet and psoriasis information on TikTok, and more.

Ruxolitinib Cream Shows Lasting Results in Pediatric Max-Use Trial

Ruxolitinib cream shows lasting safety and efficacy in children with moderate to severe atopic dermatitis.

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Robert Bissonnette, MD: Late-Breaking Data on Icotrokinra Shows Promising Efficacy and Safety in Psoriasis

Bissonnette shared highlights and insights on the icotrokinra data presented at the AAD Annual Meeting.

Empowering the Eczema Community: NEA’s Vision for Support, Education, and Awareness

Renata Block, MMS, PA-C, speaks with Wendy Smith Begolka, MBS, of the National Eczema Association about NEA’s strategic efforts in community outreach, health care provider engagement, and patient education.

The Rx Recap: March 2-8

This week, we feature top articles from our sister publications on updates in surgical management, diabetes control, and more.

VYC-17.5L Can Be Used for Safe and Effective Contouring on the Forehead

Nearly all patients in a new study saw an improved appearance in their forehead up to 12 months after treatment.

FDA Alerts of New Independent Testing for Benzoyl Peroxide Acne Products, Additional Voluntary Recalls

The agency shared details of additional voluntary recalls and its plans to release full results of its independent testing in the coming months.

Bridging the Gap Between Patient Experience and Clinical Definitions in Eczema

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C, discuss redefining eczema flares to align clinical and patient perspectives.

Improving Acne Treatment Through Antibiotic Stewardship and Gut-Skin Health

Christopher Bunick, MD, PhD, reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship, the gut-skin connection, and the importance of narrow-spectrum antibiotics at AAD 2025.

Reshaping Dermatology: The Enduring Impact of COVID-19

The COVID-19 pandemic reshaped dermatology through telehealth, social media, and increased cosmetic procedures. Challenges and opportunities persist as practices adapt.

New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis 

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

Celebrating Second Annual National Dermatologist Day with Launch of EltaMD’s ‘Derm Difference’ Campaign

EltaMD’s Derm Difference campaign honors dermatologists’ expertise in skin health, cancer prevention, and confidence-boosting care.

Novel Acne Scar Gel Has High Rates of Efficacy and Patient Satisfaction

A majority of patients noticed improvement in hyperpigmentation spots, skin texture and evenness after 12 weeks of use.

National Eczema Association Expands Visual Guide to Address Skin Tone Disparities

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C discuss the NEA's expanded eczema visual guide and upcoming Chicago event to support diverse patient communities.

Mohs Surgery Outperforms Wide Local Excision in SCC Control

An analysis of 70 studies shows that MMS reduces local recurrence to 5.0% compared to 17.7% for WLE in anogenital SCC cases.

Monica K. Li, MD: Global Innovations, Integration with Other Modalities, and Future Trends in Microneedling

Li discusses microneedling innovations, global techniques, safety, and future trends in dermatology, including integration with RF and PRP.

Mastering Dermoscopy and Dysplastic Nevi

Elizabeth Berry, MD, FAAD, reviewed dysplastic nevi as risk markers and highlighted the need for more data on severe cases at AAD 2025.

Information Related to Diet and Psoriasis on Instagram is Unreliable, According to New Analysis

99% of posts on the platform were of poor quality, according to the DISCERN instrument.

Blending Clinical Practice and Social Media with Chris Tomassian, MD

By staying authentic and leveraging real patient experiences, Tomassian ensures his content remains valuable and trustworthy.

Hyperpigmentation Advice on TikTok: Reliable or Risky?

A study analyzed TikTok’s top 50 videos on hyperpigmentation in skin of color, revealing a discrepancy between engagement and medical accuracy.

Key Insights from Novartis at AAD and AAAAI: Flexibility and Personalization in Dermatology Treatment

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

How Do Diet and Blood Zonulin Levels Impact Acne Severity?

Red meat, chocolate, milk, and foods with a high glycemic index may impact the presence of acne in patients.

Amlitelimab Demonstrates Durable Response in Atopic Dermatitis

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Home Phototherapy Proves Effective and Preferred in LITE Study for Psoriasis Treatment

The LITE study found home-based narrowband UV-B phototherapy is as effective as office-based treatment for psoriasis, with higher adherence and lower costs.

Closing Out AAD With Dermatology Times’ Editor in Chief

Christopher Bunick, MD, PhD, shares concluding remarks with colleagues at AAD 2025.

AAD 2025: Conference Recap

Catch up on all coverage from the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida, March 7-11.